Eye­point sells $100M in shares af­ter un­veil­ing eye dis­ease da­ta for drug-de­vice as­set

Eye­Point Phar­ma­ceu­ti­cals is sell­ing $100 mil­lion worth of shares on the back of pos­i­tive mid-stage da­ta for a drug-de­vice can­di­date in di­a­bet­ic mac­u­lar ede­ma. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER